July 31, 2025 · Form 4 insider transaction
Frankenius Equity AB bought 759,000 shares of TriSalus Life Sciences, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 263 days after the transaction.
Represents shares received upon conversion of the Series A Preferred Stock (the "Preferred Stock") reported in Table II.